Head And Neck Cancer Squamous Cell Carcinoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Head And Neck Cancer Squamous Cell Carcinoma – Pipeline Review, H2 2016’, provides an overview of the Head And Neck Cancer Squamous Cell Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma

The report reviews pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Head And Neck Cancer Squamous Cell Carcinoma therapeutics and enlists all their major and minor projects

The report assesses Head And Neck Cancer Squamous Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

AbbVie Inc

Accelerated Pharma, Inc.

Acceleron Pharma, Inc.

Adaptimmune Therapeutics Plc

Advaxis, Inc.

Altor BioScience Corporation

Amgen Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Bayer AG

Bionovis SA

BioNTech AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Calithera Biosciences, Inc.

CEL-SCI Corporation

Cellceutix Corporation

Celldex Therapeutics, Inc.

Centrose LLC

Critical Outcome Technologies Inc.

CytImmune Sciences, Inc.

Daiichi Sankyo Company, Limited

Eisai Co., Ltd.

Eleven Biotherapeutics Inc.

Eli Lilly and Company

Etubics Corporation

F. Hoffmann-La Roche Ltd.

G&E Herbal Biotechnology Co., Ltd.

GeneSegues Inc

Genexine, Inc.

Genmab A/S

GlaxoSmithKline Plc

Gliknik, Inc.

Glycotope GmbH

Hanmi Pharmaceuticals, Co. Ltd.

Horizon Pharma Plc

Immunomedics, Inc.

Immunovative Therapies, Ltd.

Incyte Corporation

Infinity Pharmaceuticals, Inc.

Innate Pharma S.A.

Inovio Pharmaceuticals, Inc.

IRX Therapeutics, Inc.

Johnson & Johnson

Kolltan Pharmaceuticals, Inc.

Laboratoires Pierre Fabre SA

Loxo Oncology, Inc.

Mabion SA

MacroGenics, Inc.

Marsala Biotech Inc.

Mateon Therapeutics Inc

MedImmune LLC

Merck & Co., Inc.

Merck KGaA

Merrimack Pharmaceuticals, Inc.

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc.

Molecular Partners AG

Molplex Ltd.

NanoCarrier Co., Ltd.

Novartis AG

Oncobiologics, Inc.

Oncolytics Biotech Inc.

Onconova Therapeutics, Inc.

OncoSec Medical Incorporated

Ono Pharmaceutical Co., Ltd.

Panacea Biotec Limited

PCI Biotech Holding ASA

Pfizer Inc.

Reliance Life Sciences Pvt. Ltd.

Sanofi

Shanghai Henlius Biotech Co., Ltd.

Shionogi & Co., Ltd.

Sillajen Biotherapeutics

Symphogen A/S

SynCore Biotechnology Co., Ltd.

Takara Bio Inc.

Tara Immuno-Oncology Therapeutics LLC

Transgene SA

UbiVac, LLC

VasGene Therapeutics, Inc.

VentiRx Pharmaceuticals, Inc.

Virttu Biologics Limited

Vyriad Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Head And Neck Cancer Squamous Cell Carcinoma Overview 7

Therapeutics Development 8

Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies 10

Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 17

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance 18

Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies 22

Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes 32

Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development 33

Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment 118

Drug Profiles 148

Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects 682

Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products 687

Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones 689

Appendix 704

List of Tables

List of Tables

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H2 2016 25

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma – Comparative Analysis, H2 2016 26

Number of Products under Development by Companies, H2 2016 27

Number of Products under Development by Companies, H2 2016 (Contd..1) 28

Number of Products under Development by Companies, H2 2016 (Contd..2) 29

Number of Products under Development by Companies, H2 2016 (Contd..3) 30

Number of Products under Development by Companies, H2 2016 (Contd..4) 31

Number of Products under Development by Companies, H2 2016 (Contd..5) 32

Number of Products under Development by Companies, H2 2016 (Contd..6) 33

Number of Products under Investigation by Universities/Institutes, H2 2016 34

Comparative Analysis by Late Stage Development, H2 2016 35

Comparative Analysis by Clinical Stage Development, H2 2016 36

Comparative Analysis by Early Stage Development, H2 2016 37

Comparative Analysis by Unknown Stage Development, H2 2016 38

Products under Development by Companies, H2 2016 39

Products under Development by Companies, H2 2016 (Contd..1) 40

Products under Development by Companies, H2 2016 (Contd..2) 41

Products under Development by Companies, H2 2016 (Contd..3) 42

Products under Development by Companies, H2 2016 (Contd..4) 43

Products under Development by Companies, H2 2016 (Contd..5) 44

Products under Development by Companies, H2 2016 (Contd..6) 45

Products under Development by Companies, H2 2016 (Contd..7) 46

Products under Development by Companies, H2 2016 (Contd..8) 47

Products under Development by Companies, H2 2016 (Contd..9) 48

Products under Investigation by Universities/Institutes, H2 2016 49

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by AB Science SA, H2 2016 50

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by AbbVie Inc, H2 2016 51

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Accelerated Pharma, Inc., H2 2016 52

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Acceleron Pharma, Inc., H2 2016 53

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Adaptimmune Therapeutics Plc, H2 2016 54

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Advaxis, Inc., H2 2016 55

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Altor BioScience Corporation, H2 2016 56

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Amgen Inc., H2 2016 57

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by AstraZeneca Plc, H2 2016 58

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 59

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Bayer AG, H2 2016 60

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Bionovis SA, H2 2016 61

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by BioNTech AG, H2 2016 62

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Boehringer Ingelheim GmbH, H2 2016 63

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Bristol-Myers Squibb Company, H2 2016 64

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Calithera Biosciences, Inc., H2 2016 65

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by CEL-SCI Corporation, H2 2016 66

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Cellceutix Corporation, H2 2016 67

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Celldex Therapeutics, Inc., H2 2016 68

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Centrose LLC, H2 2016 69

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Critical Outcome Technologies Inc., H2 2016 70

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by CytImmune Sciences, Inc., H2 2016 71

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 72

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Eisai Co., Ltd., H2 2016 73

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Eleven Biotherapeutics Inc., H2 2016 74

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Eli Lilly and Company, H2 2016 75

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Etubics Corporation, H2 2016 76

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 77

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2016 78

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by GeneSegues Inc, H2 2016 79

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Genexine, Inc., H2 2016 80

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Genmab A/S, H2 2016 81

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by GlaxoSmithKline Plc, H2 2016 82

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Gliknik, Inc., H2 2016 83

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Glycotope GmbH, H2 2016 84

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 85

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Horizon Pharma Plc, H2 2016 86

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Immunomedics, Inc., H2 2016 87

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Immunovative Therapies, Ltd., H2 2016 88

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Incyte Corporation, H2 2016 89

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Infinity Pharmaceuticals, Inc., H2 2016 90

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Innate Pharma S.A., H2 2016 91

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 92

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by IRX Therapeutics, Inc., H2 2016 93

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Johnson & Johnson, H2 2016 94

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 95

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Laboratoires Pierre Fabre SA, H2 2016 96

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Loxo Oncology, Inc., H2 2016 97

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Mabion SA, H2 2016 98

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by MacroGenics, Inc., H2 2016 99

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Marsala Biotech Inc., H2 2016 100

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Mateon Therapeutics Inc, H2 2016 101

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by MedImmune LLC, H2 2016 102

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Merck & Co., Inc., H2 2016 103

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Merck KGaA, H2 2016 104

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 105

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 106

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Mirati Therapeutics Inc., H2 2016 107

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Molecular Partners AG, H2 2016 108

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Molplex Ltd., H2 2016 109

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by NanoCarrier Co., Ltd., H2 2016 110

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Novartis AG, H2 2016 111

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Oncobiologics, Inc., H2 2016 112

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Oncolytics Biotech Inc., H2 2016 113

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Onconova Therapeutics, Inc., H2 2016 114

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by OncoSec Medical Incorporated, H2 2016 115

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 116

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Panacea Biotec Limited, H2 2016 117

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by PCI Biotech Holding ASA, H2 2016 118

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Pfizer Inc., H2 2016 119

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2016 120

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Sanofi, H2 2016 121

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016 122

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Shionogi & Co., Ltd., H2 2016 123

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Sillajen Biotherapeutics, H2 2016 124

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Symphogen A/S, H2 2016 125

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by SynCore Biotechnology Co., Ltd., H2 2016 126

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Takara Bio Inc., H2 2016 127

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 128

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Transgene SA, H2 2016 129

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by UbiVac, LLC, H2 2016 130

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by VasGene Therapeutics, Inc., H2 2016 131

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016 132

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Virttu Biologics Limited, H2 2016 133

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline by Vyriad Inc, H2 2016 134

Assessment by Monotherapy Products, H2 2016 135

Assessment by Combination Products, H2 2016 136

Number of Products by Stage and Target, H2 2016 138

Number of Products by Stage and Mechanism of Action, H2 2016 150

Number of Products by Stage and Route of Administration, H2 2016 162

Number of Products by Stage and Molecule Type, H2 2016 164

Head And Neck Cancer Squamous Cell Carcinoma – Dormant Projects, H2 2016 699

Head And Neck Cancer Squamous Cell Carcinoma – Dormant Projects (Contd..1), H2 2016 700

Head And Neck Cancer Squamous Cell Carcinoma – Dormant Projects (Contd..2), H2 2016 701

Head And Neck Cancer Squamous Cell Carcinoma – Dormant Projects (Contd..3), H2 2016 702

Head And Neck Cancer Squamous Cell Carcinoma – Dormant Projects (Contd..4), H2 2016 703

Head And Neck Cancer Squamous Cell Carcinoma – Discontinued Products, H2 2016 704

Head And Neck Cancer Squamous Cell Carcinoma – Discontinued Products (Contd..1), H2 2016 705

List of Figures

List of Figures

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H2 2016 25

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma – Comparative Analysis, H2 2016 26

Number of Products under Development by Companies, H2 2016 27

Number of Products under Investigation by Universities/Institutes, H2 2016 34

Comparative Analysis by Late Stage Development, H2 2016 35

Comparative Analysis by Clinical Stage Development, H2 2016 36

Comparative Analysis by Early Stage Products, H2 2016 37

Assessment by Monotherapy Products, H2 2016 135

Assessment by Combination Products, H2 2016 136

Number of Products by Top 10 Targets, H2 2016 137

Number of Products by Stage and Top 10 Targets, H2 2016 137

Number of Products by Top 10 Mechanism of Actions, H2 2016 149

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 149

Number of Products by Top 10 Routes of Administration, H2 2016 161

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 161

Number of Products by Top 10 Molecule Types, H2 2016 163

Number of Products by Stage and Top 10 Molecule Types, H2 2016 163

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports